To include your compound in the COVID-19 Resource Center, submit it here.

Hatching antibodies

OstriGen’s ostrich antibodies could yield oral therapies for GI tract diseases

OstriGen Inc. is developing polyclonal ostrich antibodies as oral therapies for cholera and other GI tract diseases that are designed to be as effective as existing mammalian antibodies while being produced at much lower costs.

Co-CEO Yasuhiro Tsukamoto, who has studied ostriches for nearly 25 years, discovered the birds readily develop antibodies in response to their environment. Like other birds, ostrich hens pass along antibodies to their eggs as

Read the full 698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE